The emergency use authorization in Taiwan is a positive development for Novavax, indicating potential for increased vaccine distribution and revenue. However, the immediate negative stock price reaction suggests that the market may have already priced in the news or that investors were expecting more impactful developments. The short-term impact is negative, but this could change if the vaccine distribution leads to significant revenue increases or if the market sentiment shifts.